Soapy's Benefits For Oncology 

Oncology patients are often considered immunocompromised. This can be due to the cancer itself or as a result of treatments such as chemotherapy, radiation therapy, or surgery, which can weaken the immune system. Cancer can impact the body's ability to produce normal amounts of immune cells, while treatments can further diminish the body's immune response to infections and diseases. 

Soap, Wash, Support

Consequently, oncology patients are at an increased risk of infections and may have a reduced capacity to fight off pathogens. Healthcare providers typically take special precautions to protect these patients from infections and may recommend specific vaccinations or prophylactic treatments to enhance their immune function.

Vulnerable Patient Population

Immunocompromised patients are at a higher risk of infections. The SoapyPro system ensures proper hand hygiene, which is crucial in preventing the spread of infections, thereby protecting these vulnerable patients.

Compliance Monitoring

Each system monitors compliance with hand hygiene protocols, which is essential in a hospital setting where immunocompromised patients are treated. Non-compliance can be detected instantly, allowing for immediate corrective action. Aligned with Leapfrog and Joint Commission requirements.

Real-time Feedback

Soapy's systems provide immediate feedback, which can help healthcare providers improve their hand hygiene practices instantly. This can significantly reduce the risk of transmitting infections to immunocompromised patients.

Data-Driven Insights

Data, that is collected by the Soapy's systems can be used to identify any gaps in hand hygiene practices, and appropriate measures can be taken to improve them. This can further reduce the risk of infections among immunocompromised patients.

Behavioral Change

SoapyPro system can help foster long-term behavioral change in hand hygiene practices among hospital staff. This can lead to a sustained reduction in the risk of infections, which is particularly beneficial for immunocompromised patients.

Reducing Cross Contamination

By ensuring that healthcare providers follow excellent hand hygiene practices, the risk of cross-contamination between patients, staff, and even hospital equipment is reduced. This is extremely important for immunocompromised patients who are susceptible to infections.


Immunocompromised (have a weakened immune system) are more likely to get sick as a result of infection exposure or be sick for a longer period. People can be immunocompromised either because of a medical condition or because they receive immunosuppressive medications or treatments. Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not limited to: 1. Active treatment for solid tumor and hematologic malignancies. 2. Hematologic malignancies associated with poor responses to vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia). 3. Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy. 4. Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy). 5. Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome). 6. Advanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV). 7. Active treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.